Renovorx announces $11.1 million at market private placement

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to renovorx, before deducting offering expenses. the proceeds from this finan.
RNXT Ratings Summary
RNXT Quant Ranking